Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, has been invited to present at the H.C. Wainwright 26th Annual Global Investment Conference in New York. Rick Barry, Cassava's Executive Chairman, will participate in a 'fireside chat' with Vernon T. Bernardino, PhD., Managing Director of Biotechnology Equity Research at H.C. Wainwright.
The event is scheduled for Monday, September 9th, from 3:00pm to 3:30pm Eastern Time. A live webcast will be available on Cassava Sciences' website, with an archived replay accessible for 90 days following the event. Registered institutional investors can request meetings with Cassava Sciences through the conference website.
Cassava Sciences, Inc. (Nasdaq: SAVA), un'azienda biotecnologica in fase clinica focalizzata sulla malattia di Alzheimer, è stata invitata a presentare alla 26a Conferenza Annuale Globale sugli Investimenti H.C. Wainwright a New York. Rick Barry, Presidente Esecutivo di Cassava, parteciperà a una 'conversazione informale' con Vernon T. Bernardino, PhD., Direttore Generale della Ricerca Azionaria Biotecnologica presso H.C. Wainwright.
L'evento è programmato per lunedì 9 settembre, dalle 15:00 alle 15:30 ora orientale. Sarà disponibile una trasmissione in diretta sul sito web di Cassava Sciences, con una registrazione archiviata accessibile per 90 giorni dopo l'evento. Gli investitori istituzionali registrati possono richiedere incontri con Cassava Sciences tramite il sito della conferenza.
Cassava Sciences, Inc. (Nasdaq: SAVA), una empresa biotecnológica en etapa clínica enfocada en la enfermedad de Alzheimer, ha sido invitada a presentar en la 26ª Conferencia Global Anual de Inversión H.C. Wainwright en Nueva York. Rick Barry, Presidente Ejecutivo de Cassava, participará en una 'charla junto al fuego' con Vernon T. Bernardino, PhD., Director General de Investigación de Equidad Biotecnológica en H.C. Wainwright.
El evento está programado para el lunes 9 de septiembre, de 3:00 p.m. a 3:30 p.m. Hora del Este. Habrá una transmisión en vivo disponible en el sitio web de Cassava Sciences, con una repetición archivada accesible durante 90 días después del evento. Los inversores institucionales registrados pueden solicitar reuniones con Cassava Sciences a través del sitio de la conferencia.
카사바 사이언스(Cassava Sciences, Inc.) (Nasdaq: SAVA)는 알츠하이머병에 집중하는 임상 단계의 생명공학 회사로, 뉴욕에서 열리는 H.C. 웨인라이트 제26회 연례 글로벌 투자 회의에 초대되었습니다. 카사바의 경영 의장인 릭 배리는 H.C. 웨인라이트에서 생명공학 주식 연구를 담당하는 베르논 T. 베르나르디노 박사와 함께 '담배를 피우는 대화'에 참여할 것입니다.
이 행사는 9월 9일 월요일 오후 3시부터 3시 30분(동부 표준시)로 예정되어 있습니다. 카사바 사이언스의 웹사이트에서는 생중계가 제공되며, 행사가 끝난 후 90일 동안 아카이브된 다시 보기를 이용할 수 있습니다. 등록된 기관 투자자는 회의 웹사이트를 통해 카사바 사이언스와의 미팅을 요청할 수 있습니다.
Cassava Sciences, Inc. (Nasdaq: SAVA), une entreprise de biotechnologie en phase clinique axée sur la maladie d'Alzheimer, a été invitée à se présenter lors de la 26ème Conférence Annuelle des Investissements Mondiaux H.C. Wainwright à New York. Rick Barry, Président Exécutif de Cassava, participera à une 'discussion au coin du feu' avec Vernon T. Bernardino, PhD., Directeur Général de la Recherche en Équité Biotechnologique chez H.C. Wainwright.
L'événement est prévu pour le lundi 9 septembre, de 15h00 à 15h30 heure de l'Est. Une diffusion en direct sera disponible sur le site web de Cassava Sciences, avec un rediffusion archivées accessible pendant 90 jours après l'événement. Les investisseurs institutionnels enregistrés peuvent demander des réunions avec Cassava Sciences via le site de la conférence.
Cassava Sciences, Inc. (Nasdaq: SAVA), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf Alzheimer konzentriert, wurde eingeladen, auf der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright in New York zu präsentieren. Rick Barry, der Executive Chairman von Cassava, wird an einem 'Feuerplatzgespräch' mit Vernon T. Bernardino, PhD., Managing Director für Biotechnologie-Aktienforschung bei H.C. Wainwright, teilnehmen.
Die Veranstaltung ist für Montag, den 9. September, von 15:00 bis 15:30 Uhr Eastern Time geplant. Eine Live-Übertragung wird auf der Website von Cassava Sciences verfügbar sein, und eine archivierte Wiederholung wird 90 Tage nach der Veranstaltung zugänglich sein. Registrierte institutionelle Investoren können über die Website der Konferenz Meetings mit Cassava Sciences anfordern.
- None.
- None.
AUSTIN, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present at the H.C. Wainwright 26th Annual Global Investment Conference, being held in New York.
Rick Barry, Cassava’s Executive Chairman, will join in a ‘fireside chat’ with Vernon T. Bernardino, PhD., Managing Director, Biotechnology Equity Research, at H.C. Wainwright.
Institutional investors who are registered for this conference may log into www.hcwevents.com to request a meeting with Cassava Sciences, pending availability.
Event details follow:
| Date: | Monday, September 9th |
| Time: | 3:00pm to 3:30 Eastern Time |
| Webcast: | https://journey.ct.events/view/d574c934-b104-45ac-bf42-07f169ce0d11 |
A live webcast will be available on the “Investors” page of Cassava Sciences’ website, www.CassavaSciences.com. An archived replay will be available for 90 days following the event.
About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain.
For More Information Contact:
Eric Schoen, Chief Financial Officer
(512) 501-2450 or ESchoen@CassavaSciences.com
FAQ
When is Cassava Sciences (SAVA) presenting at the H.C. Wainwright Global Investment Conference?
Who will represent Cassava Sciences (SAVA) at the H.C. Wainwright conference?
How can investors access Cassava Sciences' (SAVA) presentation at the H.C. Wainwright conference?
What is the focus of Cassava Sciences' (SAVA) research?
Can institutional investors meet with Cassava Sciences (SAVA) during the H.C. Wainwright conference?
